newsfilter
← Latest News
Business Wire·

Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights

– Acquisition of ALTO-207 targets Treatment-Resistant Depression (TRD) with a clinically-validated mechanism; Phase 2b trial on track to be initiated in the first half of 2026 – – External PAX-D study published in The